Industry leaders along with investment analysts rely on KMR’s R&D General Metrics Study to produce a definitive source of R&D statistics from success rates to cycle times to productivity. The study is conducted annually as part of the Pharmaceutical Benchmarking Forum and counts most of the top 20 pharma among participants. The R&D Metrix Application is a supplement tool that offers versatility and enables participants to enhance the work on their portfolio analytics from the convenience of their desktops.
The application provides invaluable, reliable information to management regarding a number of key parameters, comparing the client company against the broader industry on cycle time, attrition, pipeline, through-put (entry into the phases).
Data can be examined according to many variables, including molecule type, project type (e.g., Lead NME, supplement indication, major new formulation), whether the project was in-licensed, whether it involves co-development.
To request more information about the application contact KMR.